The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

A progressive increase in the incidence of vancomycin resistance in strains of Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Moellering et al studied the clinical efficacy and safety of quinupristin/dalfopristin (...

Full description

Saved in:
Bibliographic Details
Published in:Formulary (Cleveland, Ohio) Ohio), 2000-12, Vol.35, p.S25
Main Authors: Moellering, R C, Linden, P K, Reinhardt, J, Blumberg, E A
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Clinical trials
Drug resistance
Infectious diseases
Laboratories
Organisms
Pathogens
Patients
Penicillin
Streptococcus infections
Success
Transplants & implants
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A progressive increase in the incidence of vancomycin resistance in strains of Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Moellering et al studied the clinical efficacy and safety of quinupristin/dalfopristin (Synercid), the first injectable streptogramin antibiotic, in the treatment of VREF infection.
ISSN:1082-801X
1938-1166